ANTICOAGULATION CONTROL IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION TREATED WITH VITAMIN K ANTAGONIST THERAPY FOR 12 MONTHS OR MORE IN PRIMARY CARE IN THE UK